Gene expression analysis of cell death induction by Taurolidine in different malignant cell lines

BMC Cancer

Volumn 10, Issue 1, 2010, Pages

  Chromik, Ansgar M ^a   Hahn, Stephan A ^b   Daigeler, Adrien ^c   Flier, Annegret ^a   Bulut, Daniel ^a   May, Christina ^a   Harati, Kamran ^a   Roschinsky, Jan ^a   Sülberg, Dominique ^a   Weyhe, Dirk ^a   Mittelkötter, Ulrich ^a   Uhl, Waldemar ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Burn Centre   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TAUROLIDINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAURINE; THIADIAZINE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASPC 1 CELL; ATF3 GENE; BXPC 3 CELL; CANCER CELL LINE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CELLULAR STRESS RESPONSE; CHANG LIVER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG TARGETING; EGR1 GENE; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; HT1080 CELL; HT29 CELL LINE; HUMAN; HUMAN CELL; MITOCHONDRION; PPP1R15A GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRAF6 GENE; UBIQUITINATION; WESTERN BLOTTING; CELL SEPARATION; CELL SURVIVAL; GENETIC TRANSCRIPTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TAURINE; THIADIAZINES; TRANSCRIPTION, GENETIC;

EID: 77958541057     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-595     Document Type: Article

References (63)

1. Baker DM, Jones JA, Nguyen-Van-Tam JS, Lloyd JH, Morris DL, Bourke JB, Steele RJ, Hardcastle JD: Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg 1994, 81:1054-1056
2. Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM: Taurolidine-citrate lock solution (TauroLock) significantly reduces CVADassociated grampositive infections in pediatric cancer patients. BMC Infect Dis 2008, 8:102
3. KoldehoffM, Zakrzewski JL: Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2004, 24:491-495
4. Jacobi CA, Menenakos C, Braumann C: Taurolidine-a new drug with antitumor and anti-angiogenic effects. Anticancer Drugs 2005, 16:917-921
5. Neary PM, Hallihan P, Wang JH, Pfirrmann RW, Bouchier-Hayes DJ, Redmond HP: The Evolving Role of Taurolidine in Cancer Therapy. Ann Surg Oncol 2010, 17(4):1135-43
6. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M: The effect of taurolidine on brain tumor cells. Anticancer Res 2002, 22:809-814
7. Stendel R, Biefer HR, Dekany GM, Kubota H, Munz C, Wang S, Mohler H, Yonekawa Y, Frei K: The antibacterial substance taurolidine exhibits antineoplastic action based on a mixed type of programmed cell death. Autophagy 2009, 5:194-210
8. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma-a mouse model. J Surg Res 2007, 143:372-378
9. Sun BS, Wang JH, Liu LL, Gong SL, Redmond HP: Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol 2007, 96:241-248
10. Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 2007, 56:327-336
11. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J 2009, 34:1399-1407
12. Braumann C, Schoenbeck M, Menenakos C, Kilian M, Jacobi CA: Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. Clin Exp Metastasis 2005, 22:77-83
13. Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkotter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg 2007, 20:339-348
14. Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W, Mittelkötter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol 2008, 32:1205-1220
15. Walters DK, MuffR, Langsam B, Gruber P, Born W, Fuchs B: Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs 2007, 25:305-312
16. Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, et al: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res 2008, 27:82
17. Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK: The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol 2007, 47:697-703
18. Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol 2006, 4:34
19. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 2004, 24:1143-1147
20. Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann RW, Fiss I, Mohler H, Bigler L: Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. Clin Pharmacokinet 2007, 46:513-524
21. Darnowski JW, Goulette FA, Cousens LP, Chatterjee D, Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 2004, 54:249-258
22. Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res 2002, 22:1959-1964
23. Rodak R, Kubota H, Ishihara H, Eugster HP, Konu D, Mohler H, Yonekawa Y, Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 2005, 102:1055-1068
24. Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Mohler H: Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res 2003, 23:2309-2314
25. Rodak R, Kubota H, Ishihara H, Eugster H-P, Könü D, Möhler H, Yonekawa Y, Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 2005, 102:1055-1068
26. Chromik AM, Daigeler A, Bulut D, Flier A, May C, Harati K, Roschinsky J, Sulberg D, Ritter PR, Mittelkotter U, et al: Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Cancer Res 2010, 29:21
27. t Hoen PA, Turk R, Boer JM, Sterrenburg E, de Menezes RX, van Ommen GJ, den Dunnen JT: Intensity-based analysis of two-colour microarrays enables efficient and flexible hybridization designs. Nucleic Acids Res 2004, 32:e41
28. PfafflMW: A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001, 29:e45
29. Gashler A, Sukhatme VP: Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 1995, 50:191-224
30. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D: The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 2006, 13:115-124
31. Fan F, Jin S, Amundson SA, Tong T, Fan W, Zhao H, Zhu X, Mazzacurati L, Li X, Petrik KL, et al: ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 2002, 21:7488-7496
32. Hollander MC, Sheikh MS, Yu K, Zhan Q, Iglesias M, Woodworth C, Fornace AJ Jr: Activation of Gadd34 by diverse apoptotic signals and suppression of its growth inhibitory effects by apoptotic inhibitors. Int J Cancer 2001, 96:22-31
33. Adler HT, Chinery R, Wu DY, Kussick SJ, Payne JM, Fornace AJ Jr, Tkachuk DC: Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol 1999, 19:7050-7060
34. Ploner C, Kofler R, Villunger A: Noxa: at the tip of the balance between life and death. Oncogene 2008, 27(Suppl 1):S84-92
35. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG: Sitespecific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 2007, 282:4102-4112
36. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, Zhang S, Heldin CH, Landstrom M: The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008, 10:1199-1207
37. Braumann C, Henke W, Jacobi CA, Dubiel W: The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer 2004, 112:225-230
38. McCourt M, Wang JH, Sookhai S, Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000, 7:685-691
39. Nici L, Monfils B, Calabresi P: The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 2004, 10:7655-7661
40. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM: Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 1997, 272:20131-20138
41. Thiel G, Cibelli G: Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002, 193:287-292
42. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE: Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005, 67:356-364
43. Baek SJ, Wilson LC, Hsi LC, Eling TE: Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003, 278:5845-5853
44. Cho KN, Sukhthankar M, Lee SH, Yoon JH, Baek SJ: Green tea catechin (-)-epicatechin gallate induces tumour suppressor protein ATF3 via EGR-1 activation. Eur J Cancer 2007, 43:2404-2412
45. Yamaguchi K, Lee SH, Kim JS, Wimalasena J, Kitajima S, Baek SJ: Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res 2006, 66:2376-2384
46. Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A, Craven RJ: A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol 2005, 68:1747-1756
47. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T: Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 2006, 5:20
48. Allen-Jennings AE, Hartman MG, Kociba GJ, Hai T: The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas. J Biol Chem 2001, 276:29507-29514
49. Hai T, Hartman MG: The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 2001, 273:1-11
50. Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, Wang X, Ron D, Cavener DR, Wek RC: Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 2004, 24:1365-1377
51. Yan C, Jamaluddin MS, Aggarwal B, Myers J, Boyd DD: Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 2005, 4:233-241
52. Hartman MG, Lu D, Kim M-L, Kociba GJ, Shukri T, Buteau J, Wang X, Frankel WL, Guttridge D, Prentki M, et al: Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol 2004, 24:5721-5732
53. Lu D, Wolfgang CD, Hai T: Activating transcription factor 3, a stressinducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 2006, 281:10473-10481
54. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J 2009, 34:1399-1407
55. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A: Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009, 625:234-246
56. Kim I, Xu W, Reed JC: Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008, 7:1013-1030
57. Novoa I, Zeng H, Harding HP, Ron D: Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol 2001, 153:1011-1022
58. Novoa I, Zhang Y, Zeng H, Jungreis R, Harding HP, Ron D: Stress-induced gene expression requires programmed recovery from translational repression. EMBO J 2003, 22:1180-1187
59. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058
60. Shibue T, Taniguchi T: BH3-only proteins: integrated control point of apoptosis. Int J Cancer 2006, 119:2036-2043
61. Inoue J, Gohda J, Akiyama T: Characteristics and biological functions of TRAF6. Adv Exp Med Biol 2007, 597:72-79
62. Chung JY, Lu M, Yin Q, Lin SC, Wu H: Molecular basis for the unique specificity of TRAF6. Adv Exp Med Biol 2007, 597:122-130
63. Yang W-L, Wang J, Chan C-H, Lee S-W, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin H-K: The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009, 325:1134-1138